B7-H3 as a Novel CAR-T Therapeutic Target for Glioblastoma

Glioblastoma (GBM) remains one of the most malignant primary tumors in adults, with a 5-year survival rate less than 10% because of lacking effective treatment. Here, we aimed to explore whether B7-H3 could serve as a novel therapeutic target for GBM in chimeric antigen receptor (CAR) T cell therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Xin, Zhao, Shasha, Zhang, Yang, Wang, Yuelong, Zhang, Zongliang, Yang, Meijia, Zhu, Yanyu, Zhang, Guanjie, Guo, Gang, Tong, Aiping, Zhou, Liangxue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713854/
https://www.ncbi.nlm.nih.gov/pubmed/31485480
http://dx.doi.org/10.1016/j.omto.2019.07.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713854/
https://www.ncbi.nlm.nih.gov/pubmed/31485480
http://dx.doi.org/10.1016/j.omto.2019.07.002

Ejemplares similares